Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma Abstract #3030

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Aim(s): 1) evaluate CXCR4 expression in cell lines and patient specimens; 2) determine the preclinical efficacy and toxicity of 177Lu-Pentixather (CXCR4 antagonist) in combination with auranofin (TR inhibitor).
Materials and methods: CXCR4 expression was determined by qPCR and flow cytometry in typical, atypical carcinoid and SCLC cell lines; human LNEN specimens were examined using CXCR4 immunohistochemistry. 68Ga-Pentixafor PET imaging was performed in tumor-bearing mice. 177Lu-pentixather +/- auranofin were tested for in vitro cytotoxicity, normal organ toxicity in CD1 mice and therapeutics in tumor-bearing NSG mice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#833 The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms
Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Christiane Anne Reimann
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2745 Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
Introduction: Lung carcinoids (LCs) are rare and slow growing primary lung neuroendocrine tumors. The WHO classify LCs into atypical and typical carcinoids. Recent studies have shown that the reproducibility of LCs classification and its prognostic efficacy have high interobserver variability
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Saurabh V Laddha
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#2872 Characteristics of the Immunophenotype and the Status of Receptors for Somatostatin Type 2 and 5 of Typical and Atypical Carcinoids of the Lung
Introduction: Carcinoids of the lung are a wide range of tumors with various malignancy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Larisa Gurevich